Alzheimers Disease (AD) Diagnostics and Therapeutics Market Size, Share, Growth, and Industry Analysis, By Type (Imaging testing, Biomarker testing, Drug treatment), By Application (Hospital, Pharmacy), Regional Insights and Forecast to 2035

Unique Information about the Alzheimers Disease (AD) Diagnostics and Therapeutics Market

Alzheimers Disease (AD) Diagnostics and Therapeutics Market size is estimated at USD 11245.32 million in 2026 and is expected to reach USD 17722.07 million by 2035 at a 5.19% CAGR.

The Alzheimers Disease (AD) Diagnostics and Therapeutics Market is undergoing significant transformation due to the increasing burden of dementia cases worldwide and the emergence of disease-modifying therapies. According to global health estimates, more than 55 million individuals were living with dementia in 2024, with Alzheimer's disease accounting for approximately 60% to 70% of all dementia diagnoses. Nearly 10 million new dementia cases are identified annually, translating into approximately 1 new diagnosis every 3.2 seconds. Diagnostic innovation has accelerated, with blood-based biomarker technologies demonstrating sensitivity rates exceeding 85% in clinical validation settings. More than 140 therapeutic candidates targeting amyloid, tau, neuroinflammation, and synaptic dysfunction remain under active clinical evaluation, highlighting expanding opportunities reflected in Alzheimers Disease (AD) Diagnostics and Therapeutics Market Analysis and Alzheimers Disease (AD) Diagnostics and Therapeutics Industry Report discussions.

The United States represents a major center for the Alzheimers Disease (AD) Diagnostics and Therapeutics Market, supported by extensive clinical research activity and high diagnostic adoption. Approximately 7 million Americans aged 65 years and older were living with Alzheimer's disease in 2025, representing nearly 11% of the population within that age group. Women account for nearly 66% of diagnosed Alzheimer's patients in the country. More than 500,000 new Alzheimer's diagnoses are estimated annually among older adults. The United States hosts over 35% of ongoing Alzheimer's clinical trials globally and has witnessed increasing utilization of PET imaging, cerebrospinal fluid analysis, and blood biomarker testing. These developments continue to strengthen Alzheimers Disease (AD) Diagnostics and Therapeutics Market Insights and Alzheimers Disease (AD) Diagnostics and Therapeutics Market Outlook assessments for B2B stakeholders.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: Approximately 70% of global dementia diagnoses are attributed to Alzheimer's disease, while nearly 75% of diagnosed patients are aged above 65 years. Around 58% of therapeutic development programs focus on disease-modifying approaches, and over 62% of healthcare systems are expanding early detection initiatives to improve patient outcomes and intervention timing.
• Major Market Restraint: Nearly 48% of dementia cases remain undiagnosed in developed economies, while underdiagnosis rates exceed 75% in several low- and middle-income regions. Approximately 42% of physicians cite limited access to advanced diagnostic tools, and 37% report reimbursement-related barriers affecting adoption of novel diagnostics.
• Emerging Trends: Blood-based biomarker development represents one of the strongest trends, with approximately 86% sensitivity reported in validation studies and specificity levels approaching 90%. More than 52% of late-stage pipeline candidates target amyloid pathways, while nearly 28% focus on tau-related mechanisms and 20% emphasize neuroinflammation targets.
• Regional Leadership: North America accounts for approximately 39% of the global Alzheimer's diagnostics and therapeutics landscape, supported by extensive clinical research activity. Europe contributes nearly 29%, Asia-Pacific represents about 24%, while Middle East and Africa collectively account for approximately 8% of overall market participation.
• Competitive Landscape: The top 5 manufacturers and developers collectively account for approximately 61% of active Alzheimer's therapeutic programs. Nearly 44% of investigational therapies originate from large pharmaceutical companies, while biotechnology firms contribute around 56% of ongoing innovation efforts and early-stage pipeline developments.
• Market Segmentation: Drug treatment activities account for approximately 54% of overall market utilization, while diagnostic modalities contribute nearly 46%. Imaging testing represents around 25% of total segmentation, biomarker testing approximately 21%, hospital channels about 68%, and pharmacy channels nearly 32% of application demand.
• Recent Development: Between 2023 and 2025, approximately 19% of late-stage Alzheimer's programs advanced into pivotal evaluation phases. More than 14% of clinical candidates progressed toward regulatory review, while blood-based diagnostic implementation increased by nearly 31% across specialized neurological assessment settings.

Alzheimers Disease (AD) Diagnostics and Therapeutics Market Latest Trends

The Alzheimers Disease (AD) Diagnostics and Therapeutics Market Trends indicate a decisive transition from symptomatic treatment approaches toward early detection and disease-modifying interventions. Approximately 60% to 70% of dementia cases globally continue to be associated with Alzheimer's disease, encouraging healthcare providers to invest in predictive diagnostic technologies. Blood-based biomarker testing has emerged as a transformative innovation, with several studies reporting sensitivity exceeding 85% and specificity approaching 90% in identifying amyloid pathology among symptomatic populations. Another notable trend in the Alzheimers Disease (AD) Diagnostics and Therapeutics Market Research Report is the expansion of amyloid-targeted therapeutic development. More than 140 therapeutic candidates remain under investigation globally, with approximately 52% focused on amyloid mechanisms, 28% targeting tau pathology, and 20% addressing inflammation and synaptic dysfunction. Phase III clinical activity has expanded by nearly 18% during the past 2 years, reflecting confidence in next-generation interventions.

Digital health integration is also influencing Alzheimers Disease (AD) Diagnostics and Therapeutics Market Growth. Nearly 34% of memory assessment centers have adopted cognitive screening software incorporating artificial intelligence capabilities. Remote patient monitoring utilization increased by approximately 26% among neurological care providers, supporting continuous cognitive evaluation. PET imaging remains a cornerstone of diagnostic confirmation, accounting for approximately 57% of advanced diagnostic utilization among specialized facilities, while cerebrospinal fluid testing contributes nearly 29%. Blood biomarkers currently represent around 14% of advanced testing practices, although adoption rates continue to rise. These developments collectively shape Alzheimers Disease (AD) Diagnostics and Therapeutics Market Forecast discussions among pharmaceutical companies, diagnostic manufacturers, investors, and institutional buyers seeking long-term strategic positioning.

Alzheimers Disease (AD) Diagnostics and Therapeutics Market Dynamics

DRIVER

"Increasing prevalence of Alzheimer's disease and rising emphasis on early diagnosis"

The increasing number of Alzheimer's disease cases remains the primary growth driver highlighted in the Alzheimers Disease (AD) Diagnostics and Therapeutics Market Analysis. More than 55 million people worldwide are currently living with dementia, and approximately 60% to 70% of these cases are attributed to Alzheimer's disease. Around 10 million new dementia cases are diagnosed every year, equating to nearly 27,400 new cases each day. Individuals aged 65 years and above account for approximately 75% of Alzheimer's diagnoses globally. The population aged 65 years and older is projected to exceed 1.6 billion by 2050, compared with nearly 771 million in recent demographic estimates. This expanding elderly population has intensified demand for early screening technologies, biomarker-based testing, and advanced therapeutics. In addition, approximately 48% of healthcare organizations in developed economies have expanded dementia detection initiatives during the past 5 years. These factors continue to strengthen the Alzheimers Disease (AD) Diagnostics and Therapeutics Market Size, Alzheimers Disease (AD) Diagnostics and Therapeutics Market Outlook, and Alzheimers Disease (AD) Diagnostics and Therapeutics Industry Analysis among B2B decision-makers.

RESTRAINT

"Limited diagnosis rates and restricted access to advanced diagnostic technologies"

Despite technological advances, underdiagnosis remains a significant barrier affecting the Alzheimers Disease (AD) Diagnostics and Therapeutics Market Growth. Studies indicate that approximately 45% to 50% of dementia cases in high-income countries remain undiagnosed, while this figure exceeds 75% in several developing economies. More than 40% of primary care physicians report limited access to amyloid PET imaging facilities, and approximately 37% identify reimbursement limitations as obstacles to adopting novel diagnostic procedures. Cerebrospinal fluid testing utilization remains below 30% in many community-based healthcare settings because of procedural concerns and specialist shortages. Furthermore, nearly 33% of patients discontinue diagnostic pathways before receiving comprehensive assessments due to long waiting periods and referral delays. Variability in healthcare infrastructure also affects implementation, with some regions reporting fewer than 5 neurologists per 100,000 inhabitants. These limitations continue to influence Alzheimers Disease (AD) Diagnostics and Therapeutics Market Share dynamics and purchasing decisions among hospitals, diagnostic laboratories, and healthcare networks.

OPPORTUNITY

"Expansion of blood-based biomarkers and personalized therapeutic strategies"

Blood-based biomarker innovation is creating substantial opportunities within the Alzheimers Disease (AD) Diagnostics and Therapeutics Market Opportunities landscape. Validation studies have demonstrated sensitivity levels exceeding 85% and specificity approaching 90% for selected plasma biomarker panels associated with amyloid pathology. Compared with PET imaging procedures, blood testing can reduce assessment timelines by approximately 50% and improve accessibility across community healthcare settings. Nearly 35% of ongoing Alzheimer's diagnostic research programs are focused on plasma-based biomarkers, while approximately 22% involve multiplex testing strategies integrating genetics and protein analysis. Personalized medicine initiatives are also expanding, with almost 30% of pipeline candidates incorporating patient stratification approaches based on biomarker profiles. Artificial intelligence-assisted image interpretation has shown diagnostic accuracy improvements ranging between 12% and 18% during pilot evaluations. Such advancements are anticipated to expand testing volumes, improve early intervention rates, and support strategic partnerships highlighted in Alzheimers Disease (AD) Diagnostics and Therapeutics Market Research Report assessments.

CHALLENGE

"Complex clinical trial processes and high attrition rates in therapeutic development"

Therapeutic development in Alzheimer's disease remains associated with substantial scientific and operational challenges. Historical analyses indicate that approximately 98% of investigational Alzheimer's therapies entering clinical development fail to achieve regulatory success. Clinical trials frequently extend beyond 5 to 8 years, with patient recruitment periods often lasting 12 to 24 months. Nearly 40% of eligible participants fail screening because of strict inclusion criteria involving imaging confirmation and biomarker verification. Participant dropout rates ranging from 15% to 25% have been observed in long-duration studies. In addition, approximately 52% of late-stage programs continue to target amyloid mechanisms despite historical setbacks, increasing competitive intensity within similar therapeutic categories. Variations in disease progression measurement tools further complicate efficacy assessments, while nearly 29% of investigators report challenges related to endpoint standardization. These factors influence the strategic planning process outlined in Alzheimers Disease (AD) Diagnostics and Therapeutics Industry Report and Alzheimers Disease (AD) Diagnostics and Therapeutics Market Insights evaluations.

Segmentation Analysis

Segmentation within the Alzheimers Disease (AD) Diagnostics and Therapeutics Market reflects the growing integration of diagnostic technologies and treatment interventions. Drug treatment accounts for approximately 54% of overall utilization, while diagnostic modalities contribute nearly 46%. Imaging testing represents about 25% of the total market structure due to its established role in disease confirmation. Biomarker testing contributes approximately 21%, supported by advancements in blood- and cerebrospinal fluid-based assays. From an application perspective, hospitals account for nearly 68% of demand because of multidisciplinary neurological services and imaging capabilities, while pharmacy channels represent approximately 32%, reflecting the continued dispensing of symptomatic therapies and increasing access to disease-modifying treatments.

Download FREE Sample to learn more about this report.

By Type

Imaging Testing: Imaging testing remains a foundational segment within the Alzheimers Disease (AD) Diagnostics and Therapeutics Market, accounting for approximately 25% of overall market share. Amyloid PET imaging utilization has increased by nearly 18% over the past several years in specialized neurological centers. PET imaging contributes approximately 57% of advanced diagnostic procedures due to its ability to visualize amyloid deposition before severe symptom progression. Magnetic resonance imaging (MRI) continues to support differential diagnosis, with more than 70% of suspected Alzheimer's patients undergoing MRI assessment during initial evaluations.

Biomarker Testing: Biomarker testing accounts for approximately 21% of the Alzheimers Disease (AD) Diagnostics and Therapeutics Market and represents one of the fastest-evolving segments. Cerebrospinal fluid analysis currently contributes nearly 29% of advanced testing utilization, measuring biomarkers such as beta-amyloid and tau proteins. Blood-based biomarker assays have demonstrated sensitivity levels exceeding 85% and specificity approaching 90% in selected validation studies. Approximately 35% of ongoing diagnostic research programs focus on plasma biomarkers because of their convenience and scalability.

Drug Treatment: Drug treatment constitutes the largest segment, representing approximately 54% of the Alzheimers Disease (AD) Diagnostics and Therapeutics Market Size. Symptomatic therapies, including cholinesterase inhibitors and NMDA receptor antagonists, remain widely prescribed and are utilized by nearly 70% of diagnosed patients receiving pharmacological intervention. Disease-modifying approaches have gained momentum, with more than 140 therapeutic candidates under clinical evaluation globally. Approximately 52% of investigational agents target amyloid pathways, while 28% focus on tau mechanisms and 20% address inflammation and synaptic dysfunction.

By Application

Hospital: Hospitals represent the dominant application segment in the Alzheimers Disease (AD) Diagnostics and Therapeutics Market, accounting for approximately 68% of overall utilization. The high share is attributed to the availability of multidisciplinary neurological teams, advanced imaging infrastructure, and integrated patient management pathways. More than 72% of Alzheimer's patients requiring comprehensive cognitive evaluation undergo their initial assessments in hospital settings. Approximately 80% of tertiary care hospitals in developed healthcare systems possess MRI capabilities, while nearly 45% maintain access to PET imaging either on-site or through affiliated diagnostic centers.

Pharmacy: Pharmacies account for approximately 32% of the Alzheimers Disease (AD) Diagnostics and Therapeutics Market by application and remain essential distribution channels for both symptomatic and emerging therapeutic products. More than 70% of patients receiving cholinesterase inhibitors obtain their medications through retail and hospital pharmacy networks. Community pharmacies contribute significantly to treatment adherence, with approximately 61% of caregivers relying on pharmacists for medication counseling and refill management.

Regional Outlook

The Alzheimers Disease (AD) Diagnostics and Therapeutics Market demonstrates diverse regional performance influenced by aging demographics, healthcare infrastructure, diagnostic accessibility, and clinical research intensity. North America leads with approximately 39% market share, followed by Europe at 29%, Asia-Pacific at 24%, and the Middle East & Africa at 8%. Rising dementia prevalence, expanding biomarker adoption, and increasing neurological care investments continue to shape regional demand patterns and strategic market opportunities.

Download FREE Sample to learn more about this report.

North America

North America leads the Alzheimers Disease (AD) Diagnostics and Therapeutics Market with an estimated share of approximately 39%. The region benefits from high awareness levels, established reimbursement mechanisms, and advanced healthcare infrastructure. The United States accounts for the majority of regional activity, with approximately 7 million Americans aged 65 years and older living with Alzheimer's disease. This number is expected to rise substantially as demographic shifts continue, with adults aged 65 years and above representing nearly 17% of the national population. More than 35% of global Alzheimer's clinical trials are conducted within North America, reflecting strong research capabilities and access to specialized patient populations. Approximately 46% of tertiary hospitals maintain access to PET imaging for amyloid assessment, while MRI availability exceeds 85% among major neurological centers.

Blood-based biomarker adoption has accelerated, with pilot implementation programs expanding by nearly 30% across memory clinics. Women represent approximately 66% of Alzheimer's patients in the region, highlighting the importance of gender-specific care considerations. Nearly 58% of diagnosed individuals receive pharmacological intervention, while participation in structured cognitive support programs exceeds 34%. Government-supported dementia action plans and educational campaigns continue to improve diagnosis rates, although approximately 45% of cases remain undetected during early stages. These factors reinforce North America's leadership position in Alzheimers Disease (AD) Diagnostics and Therapeutics Market Analysis and investment prioritization.

Europe

Europe accounts for approximately 29% of the Alzheimers Disease (AD) Diagnostics and Therapeutics Market Share and remains a major contributor to innovation and patient care initiatives. The region is home to more than 10 million individuals living with dementia, with Alzheimer's disease representing nearly 60% to 70% of these cases. Countries with aging populations report that individuals aged 65 years and above comprise between 20% and 24% of total residents, increasing demand for specialized neurological services. Approximately 41% of European memory clinics utilize cerebrospinal fluid biomarker testing as part of routine diagnostic evaluations, while PET imaging access has expanded to nearly 32% of specialized facilities.

MRI remains the most widely available imaging modality, present in more than 82% of tertiary healthcare institutions. Clinical research participation remains robust, with Europe hosting nearly 30% of ongoing Alzheimer's therapeutic studies. Public awareness initiatives have improved diagnostic engagement, resulting in approximately 18% increases in referrals to memory assessment services in selected healthcare systems. Nearly 63% of diagnosed patients receive symptomatic pharmacological treatment, and approximately 12% participate in structured non-pharmacological interventions focused on cognition and quality of life. Despite these advances, underdiagnosis rates remain close to 50% in some communities, emphasizing the need for broader screening implementation. These trends continue to influence Alzheimers Disease (AD) Diagnostics and Therapeutics Industry Report findings and regional strategic planning.

Asia-Pacific

Asia-Pacific accounts for approximately 24% of the Alzheimers Disease (AD) Diagnostics and Therapeutics Market Share and is emerging as one of the most significant regions for future expansion due to demographic transitions and improving healthcare accessibility. The region is home to more than 60% of the global population and contains some of the world's fastest-growing elderly populations. Individuals aged 65 years and above already exceed 450 million across Asia-Pacific, and this figure continues to increase annually. Dementia prevalence in several Asia-Pacific countries ranges between 5% and 8% among populations older than 60 years, with Alzheimer's disease accounting for nearly 60% to 70% of all dementia diagnoses. Japan remains one of the most mature Alzheimer's care markets in the region, with approximately 29% of its population aged 65 years and older. China has more than 15 million individuals living with dementia, representing one of the largest patient pools globally. India is also experiencing a rising disease burden, with dementia prevalence estimates ranging from 2% to 4% among older adults in community studies.

Diagnostic capabilities continue to improve throughout Asia-Pacific. MRI availability exceeds 70% in major urban tertiary hospitals, while PET imaging access remains concentrated within specialized centers and accounts for approximately 18% of advanced diagnostic utilization. Blood-based biomarker implementation has expanded by nearly 24% in pilot neurological programs due to its lower invasiveness and broader scalability. Approximately 27% of ongoing Alzheimer's studies now include recruitment sites across Asia-Pacific, reflecting increasing regional participation in multinational clinical development. Pharmacological intervention rates vary substantially throughout the region. Nearly 52% of diagnosed patients in developed Asia-Pacific healthcare systems receive medication-based management, compared with approximately 28% to 35% in lower-resource settings. Government initiatives supporting healthy aging, cognitive screening, and dementia awareness have increased memory clinic visits by approximately 16% in selected countries.

Middle East & Africa

The Middle East & Africa region represents approximately 8% of the Alzheimers Disease (AD) Diagnostics and Therapeutics Market and demonstrates gradual but measurable progress in diagnostic infrastructure and treatment accessibility. Although regional healthcare systems vary considerably, improvements in neurological services and aging population trends continue to influence market development. Individuals aged 60 years and older account for nearly 7% to 10% of the regional population, and this proportion is increasing steadily due to improvements in life expectancy and healthcare access. Dementia prevalence estimates within Middle Eastern and African populations range between 2% and 6% among adults aged over 65 years, with Alzheimer's disease contributing approximately 60% to 70% of total dementia diagnoses. Underdiagnosis remains a major concern, with nearly 70% to 80% of dementia cases believed to remain unidentified in several lower-resource environments. Limited public awareness and restricted specialist availability contribute to delayed diagnosis and treatment initiation.

MRI availability has expanded across urban tertiary healthcare facilities, reaching approximately 48% of major hospitals, while PET imaging access remains limited and accounts for less than 10% of advanced diagnostic procedures. Cerebrospinal fluid biomarker testing is available in nearly 22% of specialized neurological institutions, primarily within larger metropolitan centers. Blood-based biomarker initiatives are beginning to emerge through academic collaborations and pilot implementation projects. Approximately 38% of diagnosed Alzheimer's patients in the region receive pharmacological treatment, reflecting disparities in healthcare access and affordability. Specialist workforce shortages remain evident, with some countries reporting fewer than 3 neurologists per 100,000 inhabitants. Despite these challenges, dementia awareness campaigns have improved healthcare engagement, increasing memory-related consultations by approximately 11% in selected healthcare systems.

Investment Analysis and Opportunities

Investment activity within the Alzheimers Disease (AD) Diagnostics and Therapeutics Market has intensified as healthcare systems prioritize early intervention and disease modification. More than 140 therapeutic candidates remain under active investigation globally, creating opportunities across diagnostics, treatment development, digital health, and companion technologies. Approximately 52% of pipeline assets target amyloid-related mechanisms, while 28% focus on tau pathology and 20% address neuroinflammation and alternative biological pathways. Diagnostic innovation represents a particularly attractive investment segment. Nearly 35% of ongoing diagnostic programs focus on blood-based biomarkers due to their potential to improve accessibility and reduce procedural complexity. Validation studies reporting sensitivity above 85% and specificity approaching 90% have increased investor confidence in plasma-based testing platforms. Artificial intelligence applications within neuroimaging have demonstrated diagnostic accuracy improvements ranging from 12% to 18%, encouraging partnerships between technology providers and healthcare institutions.

Clinical trial infrastructure also presents substantial opportunities. Approximately 27% of multinational Alzheimer's studies now include Asia-Pacific recruitment sites, reflecting geographic diversification strategies. Patient recruitment platforms, remote monitoring technologies, and decentralized trial models have expanded by nearly 23% to improve enrollment efficiency and retention rates. Institutional investors increasingly evaluate organizations with integrated capabilities spanning diagnostics and therapeutics. Approximately 31% of strategic collaborations announced in the neurological sector involve biomarker development partnerships. The growing elderly population, combined with the fact that nearly 10 million new dementia cases emerge annually worldwide, continues to support long-term opportunity assessments highlighted in Alzheimers Disease (AD) Diagnostics and Therapeutics Market Research Report analyses.

New Product Development

New product development within the Alzheimers Disease (AD) Diagnostics and Therapeutics Market is increasingly focused on disease modification, early diagnosis, and precision medicine approaches. More than 140 therapeutic candidates are currently progressing through various stages of clinical development worldwide. Approximately 52% of these investigational therapies target amyloid-beta pathology, while 28% focus on tau protein aggregation and nearly 20% address neuroinflammation, synaptic dysfunction, and other emerging mechanisms associated with neurodegeneration. Blood-based diagnostic innovation represents one of the most significant areas of advancement. Approximately 35% of ongoing Alzheimer's diagnostic research programs are dedicated to plasma biomarkers capable of detecting disease pathology before substantial cognitive decline occurs. Clinical validation studies have demonstrated sensitivity rates exceeding 85% and specificity approaching 90% for selected biomarker panels. Compared with traditional imaging pathways, blood-based assays may reduce diagnostic timelines by nearly 50%, supporting broader adoption across community healthcare environments.

Artificial intelligence integration is also transforming product development. Machine-learning algorithms applied to neuroimaging datasets have improved diagnostic accuracy by approximately 12% to 18% in pilot evaluations. Digital cognitive assessment platforms capable of remote screening have expanded by nearly 26% among memory care providers, enabling earlier identification of high-risk individuals and improved patient monitoring. Combination therapies are emerging as another area of innovation, with approximately 16% of active therapeutic programs investigating multi-target approaches designed to address several pathological pathways simultaneously. Long-acting formulations and patient-friendly administration methods are also gaining attention, particularly among elderly populations requiring sustained treatment adherence. These advances continue to reshape Alzheimers Disease (AD) Diagnostics and Therapeutics Market Trends and product differentiation strategies for manufacturers.

Five Recent Developments (2023–2025)

• Eisai expanded late-stage Alzheimer's therapeutic implementation activities during 2023–2024, with clinical programs involving more than 1,700 participants and demonstrating measurable reductions of approximately 27% in cognitive decline progression compared with control populations over specified observation periods.
• Roche advanced its Alzheimer's pipeline through large multinational investigations between 2023 and 2025, enrolling more than 1,900 participants across numerous study sites while expanding biomarker-driven patient selection strategies to improve treatment precision.
• Blood-based biomarker technologies entered broader validation phases during 2024, with several studies reporting sensitivity above 85% and specificity approaching 90%, supporting efforts to increase accessibility beyond specialized imaging centers.
• Artificial intelligence applications in neurodiagnostics expanded significantly from 2023 to 2025, improving image interpretation efficiency by approximately 15% and increasing diagnostic consistency among trained evaluators in pilot implementation programs.
• Global Alzheimer's clinical development activity intensified through 2025, with more than 140 active therapeutic candidates under evaluation and approximately 18% growth in Phase III investigations focusing on disease-modifying approaches and personalized treatment strategies.

Report Coverage of Alzheimers Disease (AD) Diagnostics and Therapeutics Market

The Alzheimers Disease (AD) Diagnostics and Therapeutics Market Report provides comprehensive coverage of diagnostic technologies, therapeutic interventions, competitive positioning, segmentation trends, regional performance, and innovation pipelines shaping the industry landscape. The report evaluates the global burden of Alzheimer's disease, which accounts for approximately 60% to 70% of all dementia cases among the more than 55 million individuals currently living with dementia worldwide. Coverage includes detailed assessment of key diagnostic categories such as imaging testing, biomarker testing, and emerging blood-based assays. Imaging technologies currently represent approximately 25% of market segmentation, while biomarker testing contrib